NYSE$PEN

Penumbra Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Penumbra's Q4 2023 financial results were reported, highlighting revenue growth and strategic shifts in product categories.

Penumbra, Inc. reported a strong fourth quarter in 2023, with revenue reaching $284.7 million, a 28.7% increase compared to Q4 2022. The company's thrombectomy product sales grew significantly, driving overall revenue growth. Penumbra is strategically shifting its product revenue categories to provide more meaningful insights to investors.

  • Total revenue increased by 28.7% to $284.7 million compared to Q4 2022.
  • Thrombectomy product revenue grew by 42.4% to $190.8 million.
  • Net income was reported at $54.2 million with an adjusted EBITDA of $53.4 million, representing an 18.8% adjusted EBITDA margin.
  • The company projects total revenue growth of 16% to 20% for 2024.

Headline financials

Total Revenue

$285M

Previous: $221M+28.7%
EPS (adj)

$0.76

Previous: $0.16+375.0%
Gross Margin

65.7%

Previous: 62.6%+5.0%
Adjusted EBITDA Margin

18.8%

No prior period
Capital Expenditures

-$3.65M

Previous: $3.56M-202.3%
Net Income

$54.2M

Previous: $3.88M+1298.5%
Operating Income

$35M

Previous: $4.83M+624.8%
Gross Profit

$187M

Previous: $138M+35.1%
R&D Expense

$21.9M

No prior period
Stock-Based Comp

$10.8M

Previous: $10M+7.9%

Revenue & EPS history

Penumbra · Revenue · Quarterly

$285M

Q4 2023+28.7%vs Q4 2022
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

Penumbra · $271M total across 2 segments · Q3 2023

  • Thrombectomy
    $179M
  • Embolization and Access
    $91.9M

Forward guidance

Penumbra projects total revenue growth of 16% to 20% in 2024. The Company projects U.S. thrombectomy growth of 27% to 30%. Gross margin expansion is expected to be 100 to 150 basis points, and non-GAAP operating margin expansion is expected to be 100 to 200 basis points, compared to full year 2023.

Tailwinds

  • Projected total revenue growth of 16% to 20% for 2024.
  • U.S. thrombectomy growth projected at 27% to 30%.
  • Gross margin expansion expected to be 100 to 150 basis points.
  • Non-GAAP operating margin expansion expected to be 100 to 200 basis points.
  • Driven primarily by Computer-Assisted Vacuum Thrombectomy (“CAVT”) products

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+2.0%

Avg return

Earnings day

+1.3%

Avg return

5 days after

+1.9%

Avg return

30 days after

57%

28 / 49 earnings

Positive

+23.4%

Q4 2014

Best reaction

-15.8%

Q2 2018

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.1%-0.7%-1.1%
Q4 2025+0.9%+0.4%-1.1%
Q3 2025+17.1%+24.0%+33.3%
Q1 2025+7.0%+6.5%-3.7%
Q4 2024+12.0%+6.1%+3.4%
Q3 2024+9.2%+9.5%+16.5%
Q2 2024-6.3%-1.6%+13.5%
Q1 2024-4.0%+0.3%-7.2%
Q4 2023-7.7%-10.1%-13.0%
Q3 2023+2.0%+1.3%+17.4%
Q2 2023-11.2%-16.8%-12.8%
Q1 2023+5.5%+8.6%+10.1%
Q4 2022+2.3%-0.5%+5.1%
Q3 2022+3.0%+12.0%+34.0%
Q2 2022+13.7%+8.7%+12.5%
Q1 2022-3.6%-15.3%-17.6%
Q4 2021-3.4%+5.6%-2.6%
Q3 2021+3.0%-1.8%-14.8%
Q2 2021-2.1%-2.4%+3.0%
Q1 2021-8.3%-8.9%-13.9%
Q4 2020+3.2%+1.6%-3.4%
Q3 2020+10.6%+3.9%-5.1%
Q2 2020+2.5%+5.5%-3.5%
Q1 2020+1.4%+2.4%+1.4%
Q4 2019-6.8%-10.0%-13.7%
Q3 2019-0.8%+0.6%+1.0%
Q2 2019-6.9%-6.5%-15.1%
Q1 2019+3.0%-0.2%+17.8%
Q4 2018-11.2%-5.7%-1.1%
Q3 2018+7.2%+9.0%+1.1%
Q2 2018-15.8%-16.0%-3.8%
Q1 2018+9.5%+10.2%+15.7%
Q4 2017+3.9%+8.4%+11.0%
Q3 2017+9.3%+2.3%-3.3%
Q2 2017+5.8%+4.1%+4.4%
Q1 2017+4.3%-2.3%+1.0%
Q4 2016+3.8%+5.2%+7.8%
Q3 2016-2.5%+2.4%-4.2%
Q2 2016+10.9%+10.8%+6.6%
Q1 2016-1.7%
Q1 2015-1.7%
Q2 2014-6.3%
Q4 2015-6.3%
Q4 2013-6.3%
Q2 2015-6.3%
Q1 2014-6.3%
Q3 2014+23.4%
Q3 2015+23.4%
Q4 2014+23.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro